anti cd56 fitc (Miltenyi Biotec)
Miltenyi Biotec is a verified supplier 
Miltenyi Biotec manufactures this product 
96
Structured Review
Miltenyi Biotec
anti cd56 fitc
Anti Cd56 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 42 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd56+fitc/PSA-NCAM+Antibody%2C+anti-human%2Fmouse%2Frat/pm41975066-401-27-33
Average 96 stars, based on 42 article reviews
Anti Cd56 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 42 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd56+fitc/PSA-NCAM+Antibody%2C+anti-human%2Fmouse%2Frat/pm41975066-401-27-33
Average 96 stars, based on 42 article reviews
anti cd56 fitc - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
Expressing:Article Title: Optimization of hypo-alloimmunogenic multispecific CAR-T and SARS-CoV-2-specific T cells for off-the-shelf adoptive cell therapy Article Snippet: Cells acquisition and analysis was performed by BD LSRII and FlowJo, respectively (BD Bioscience). .. Antibodies to use: human CD45-APC (2D1; cat. 17-9459-42) and human HLA-ABC-PE (W6/32; cat. 12-9983-42) (both from eBioscience) for B2M KO; Biotin-CD19 CAR Detection Reagent (which recombinantly expressed fusion protein consisting of the human CD19 extracellular domains; cat. 130-115-965) and Streptavidin-APC-Vio 770 (cat. 130-106-794) for CAR expression; CD45-vioblue (5B1; cat. 130-113-122), CD3-FITC (REA613; cat. 130-113-138), CD4-viogreen (REA623; cat. 130-113-230), CD8-APC-vio770 (REA734; cat. 130-110-681), CD56-PE (REA196; cat. 130-113-312), CD14-APC (REA599; cat. 130-110-520), and CD19-PE-vio770 (REA675; cat. 130-113-647) for immune composition; CD3-FITC (REA613), CD45RO-APC-vio770 (REA611; cat. 130-113-557), and CD62L-PE (REA615; cat. 130-114-151) (all from Miltenyi Biotec) for T cell subsets of SARS-CoV-2-specific T cells; CD3-FITC, HLA-ABC-PE, and HLA-E (3D12; cat. 342606, Biolegend) for knockin analysis; CD3-BV421 (UCHT1; cat. 300434, BioLegend), Article Title: Optimization of Hypo-alloimmunogenic Multispecific CAR-T Cells and SARS-CoV-2-Specific T Cells for Off-the-shelf Adoptive Cell Therapy Article Snippet: Cells acquisition and analysis was performed by BD LSRII and 503 Flowjo respectively (BD bioscience). .. Antibodies to use: human CD45-APC (2D1; cat. 17-9459-42), 504 human HLA-ABC-PE (W6/32; cat. 12-9983-42) (both from eBioscience) for B2M knockout; biotin-CD19 505 CAR detection Reagent (which recombinantly expressed fusion protein consisting of the human CD19 506 extracellular domains; cat. 130-115-965) and streptavidin-APC-Vio® 770 (cat. 130-106-794) for CAR 507 expression; CD45-vioblue (5B1; cat. 130-113-122), CD3-FITC (REA613; cat. 130-113-138), CD4-508 viogreen (REA623; cat. 130-113-230), CD8-APC-vio770 (REA734; cat. 130-110-681), CD56-PE (REA196; 509 cat. 130-113-312), CD14-APC (REA599; cat. 130-110-520) and CD19-PE-vio770 (REA675; cat. 130-113-510 647) for immune composition; CD3-FITC (REA613), CD45RO-APC-vio770 (REA611; cat. 130-113-557) 511 and CD62L-PE (REA615; cat. 130-114-151) (all from Miltenyi biotec) for T cell subsets of SARS-CoV-2-512 specific T cells; CD3-FITC, HLA-ABC-PE and HLA-E (3D12; cat. 342606, Biolegend) for knock-in analysis; 513 CD3-BV421 (UCHT1; cat. 300434, Biolegend), Article Title: The impact of anticoagulant used for peripheral blood collection on NK cell yield, function, and proliferation. Article Snippet: Natural killer (NK) cells are under investigation for cellular immunotherapy of cancer, infectious diseases, and autoimmunity.. The collection of autologous or allogeneic starting material for the expansion of NK cells whether whole blood, cord blood, or leukocyte apheresis requires the use of anticoagulants.. Heparin and acid citrate dextrose A (ACD-A) are most commonly used for collection, but their impact on NK cells has not been clearly described. Knock-In:Article Title: Optimization of hypo-alloimmunogenic multispecific CAR-T and SARS-CoV-2-specific T cells for off-the-shelf adoptive cell therapy Article Snippet: Cells acquisition and analysis was performed by BD LSRII and FlowJo, respectively (BD Bioscience). .. Antibodies to use: human CD45-APC (2D1; cat. 17-9459-42) and human HLA-ABC-PE (W6/32; cat. 12-9983-42) (both from eBioscience) for B2M KO; Biotin-CD19 CAR Detection Reagent (which recombinantly expressed fusion protein consisting of the human CD19 extracellular domains; cat. 130-115-965) and Streptavidin-APC-Vio 770 (cat. 130-106-794) for CAR expression; CD45-vioblue (5B1; cat. 130-113-122), CD3-FITC (REA613; cat. 130-113-138), CD4-viogreen (REA623; cat. 130-113-230), CD8-APC-vio770 (REA734; cat. 130-110-681), CD56-PE (REA196; cat. 130-113-312), CD14-APC (REA599; cat. 130-110-520), and CD19-PE-vio770 (REA675; cat. 130-113-647) for immune composition; CD3-FITC (REA613), CD45RO-APC-vio770 (REA611; cat. 130-113-557), and CD62L-PE (REA615; cat. 130-114-151) (all from Miltenyi Biotec) for T cell subsets of SARS-CoV-2-specific T cells; CD3-FITC, HLA-ABC-PE, and HLA-E (3D12; cat. 342606, Biolegend) for knockin analysis; CD3-BV421 (UCHT1; cat. 300434, BioLegend), Article Title: Optimization of Hypo-alloimmunogenic Multispecific CAR-T Cells and SARS-CoV-2-Specific T Cells for Off-the-shelf Adoptive Cell Therapy Article Snippet: Cells acquisition and analysis was performed by BD LSRII and 503 Flowjo respectively (BD bioscience). .. Antibodies to use: human CD45-APC (2D1; cat. 17-9459-42), 504 human HLA-ABC-PE (W6/32; cat. 12-9983-42) (both from eBioscience) for B2M knockout; biotin-CD19 505 CAR detection Reagent (which recombinantly expressed fusion protein consisting of the human CD19 506 extracellular domains; cat. 130-115-965) and streptavidin-APC-Vio® 770 (cat. 130-106-794) for CAR 507 expression; CD45-vioblue (5B1; cat. 130-113-122), CD3-FITC (REA613; cat. 130-113-138), CD4-508 viogreen (REA623; cat. 130-113-230), CD8-APC-vio770 (REA734; cat. 130-110-681), CD56-PE (REA196; 509 cat. 130-113-312), CD14-APC (REA599; cat. 130-110-520) and CD19-PE-vio770 (REA675; cat. 130-113-510 647) for immune composition; CD3-FITC (REA613), CD45RO-APC-vio770 (REA611; cat. 130-113-557) 511 and CD62L-PE (REA615; cat. 130-114-151) (all from Miltenyi biotec) for T cell subsets of SARS-CoV-2-512 specific T cells; CD3-FITC, HLA-ABC-PE and HLA-E (3D12; cat. 342606, Biolegend) for knock-in analysis; 513 CD3-BV421 (UCHT1; cat. 300434, Biolegend), Staining:Article Title: HLA-G neo-expression modifies genetic programs governing tumor cell lines Article Snippet: .. The following antibodies were used for cell surface staining: MEM-G/9-PE (anti-HLA-G1) from Exbio (Praha, a.s.); ILT2-PE (Clone: HP-F1) and ILT4-PE from eBioscience (San Diego, CA, U.S.); CD147-PE, SDC2-APC; CD56-PE, Article Title: Interferon-gamma biased agonists Article Snippet: Human blood DCs were enriched from blood in leukoreduction system chambers by Ficoll-Hypaque density gradient centrifugation, followed by magnetic enrichment with the EasySep Human Myeloid DC Enrichment kit (19061; StemCell Technologies). .. Enriched cells were stained with DAPI and lineage markers CD19 PE-Cy5 (Beckman Coulter); Article Title: The impact of anticoagulant used for peripheral blood collection on NK cell yield, function, and proliferation. Article Snippet: Natural killer (NK) cells are under investigation for cellular immunotherapy of cancer, infectious diseases, and autoimmunity.. The collection of autologous or allogeneic starting material for the expansion of NK cells whether whole blood, cord blood, or leukocyte apheresis requires the use of anticoagulants.. Heparin and acid citrate dextrose A (ACD-A) are most commonly used for collection, but their impact on NK cells has not been clearly described. Knock-Out:Article Title: Optimization of Hypo-alloimmunogenic Multispecific CAR-T Cells and SARS-CoV-2-Specific T Cells for Off-the-shelf Adoptive Cell Therapy Article Snippet: Cells acquisition and analysis was performed by BD LSRII and 503 Flowjo respectively (BD bioscience). .. Antibodies to use: human CD45-APC (2D1; cat. 17-9459-42), 504 human HLA-ABC-PE (W6/32; cat. 12-9983-42) (both from eBioscience) for B2M knockout; biotin-CD19 505 CAR detection Reagent (which recombinantly expressed fusion protein consisting of the human CD19 506 extracellular domains; cat. 130-115-965) and streptavidin-APC-Vio® 770 (cat. 130-106-794) for CAR 507 expression; CD45-vioblue (5B1; cat. 130-113-122), CD3-FITC (REA613; cat. 130-113-138), CD4-508 viogreen (REA623; cat. 130-113-230), CD8-APC-vio770 (REA734; cat. 130-110-681), CD56-PE (REA196; 509 cat. 130-113-312), CD14-APC (REA599; cat. 130-110-520) and CD19-PE-vio770 (REA675; cat. 130-113-510 647) for immune composition; CD3-FITC (REA613), CD45RO-APC-vio770 (REA611; cat. 130-113-557) 511 and CD62L-PE (REA615; cat. 130-114-151) (all from Miltenyi biotec) for T cell subsets of SARS-CoV-2-512 specific T cells; CD3-FITC, HLA-ABC-PE and HLA-E (3D12; cat. 342606, Biolegend) for knock-in analysis; 513 CD3-BV421 (UCHT1; cat. 300434, Biolegend), Blocking Assay:Article Title: The impact of anticoagulant used for peripheral blood collection on NK cell yield, function, and proliferation. Article Snippet: Natural killer (NK) cells are under investigation for cellular immunotherapy of cancer, infectious diseases, and autoimmunity.. The collection of autologous or allogeneic starting material for the expansion of NK cells whether whole blood, cord blood, or leukocyte apheresis requires the use of anticoagulants.. Heparin and acid citrate dextrose A (ACD-A) are most commonly used for collection, but their impact on NK cells has not been clearly described. Saline:Article Title: The impact of anticoagulant used for peripheral blood collection on NK cell yield, function, and proliferation. Article Snippet: Natural killer (NK) cells are under investigation for cellular immunotherapy of cancer, infectious diseases, and autoimmunity.. The collection of autologous or allogeneic starting material for the expansion of NK cells whether whole blood, cord blood, or leukocyte apheresis requires the use of anticoagulants.. Heparin and acid citrate dextrose A (ACD-A) are most commonly used for collection, but their impact on NK cells has not been clearly described. Labeling:Article Title: HLA I immunopeptidome of synthetic long peptide pulsed human dendritic cells for therapeutic vaccine design. Article Snippet: Anti-human protein antibodies used for moDC analysis were: CD45APCeFluor780 (0.31 μg/mL; HI30, Thermo Fisher), CD14-eFluor450 npj Vaccines | (2025) 10:12 10 (2 μg/mL; 61D3, Thermo Fisher), CD1a-APC (0.15 μg/mL; HI149, BD Pharmingen), DC-SIGN-PerCP-Cy5.5 (0.08 μg/mL; DCN46, BD Pharmingen), CD11c-FITC (5 μg/mL; KB90, Dako), CD80-FITC (5 μg/mL; MAB104, Thermo Fisher), CD83-APC (0.67 μg/mL; HB15e, Thermo Fisher), HLA-DR-PE (0.02 μg/mL; LN3, Thermo Fisher), CD40-PerCPeFluor710 (0.08 μg/mL; 5C3, Thermo Fisher), and the viability dye AQUA Live/Dead-AmCyan (1:200; Invitrogen). .. Anti-human protein antibodies used for primary DC analysis were: CD45-eFluor450 (0.625 μg/mL, HI30, Thermo Fisher), CD19-FITC (2 μg/mL, HIB19, Thermo Fisher), CD3FITC (1.25 μg/mL, UCHT1, Thermo Fisher), CD14-FITC (2 μg/mL, 61D3, Thermo Fisher), |
